From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

Jonathan D Licht; Jake Shortt; Ricky W Johnstone

doi:10.1016/j.ccr.2013.12.019

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

Jonathan D Licht, Jake Shortt, Ricky W Johnstone

Research output: Contribution to journal › Editorial › Other › peer-review

25 Citations (Scopus)

Abstract

Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.

Original language	English
Pages (from-to)	9 - 11
Number of pages	3
Journal	Cancer Cell
Volume	25
Issue number	1
DOIs	https://doi.org/10.1016/j.ccr.2013.12.019
Publication status	Published - 2014
Externally published	Yes

Access to Document

10.1016/j.ccr.2013.12.019

Cite this

@article{53ed13ebb0904812b6d08ef9009e927a,

title = "From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma",

abstract = "Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.",

author = "Licht, {Jonathan D} and Jake Shortt and Johnstone, {Ricky W}",

year = "2014",

doi = "10.1016/j.ccr.2013.12.019",

language = "English",

volume = "25",

pages = "9 -- 11",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

AU - Licht, Jonathan D

AU - Shortt, Jake

AU - Johnstone, Ricky W

PY - 2014

Y1 - 2014

N2 - Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.

AB - Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for MM growth.

U2 - 10.1016/j.ccr.2013.12.019

DO - 10.1016/j.ccr.2013.12.019

M3 - Editorial

SN - 1535-6108

VL - 25

SP - 9

EP - 11

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -